Black Diamond Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$3.60(as of May 20, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Black Diamond Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$3.60
Ticker SymbolBDTX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees21
CountyUSA
Market Cap$171.9M
EBIDTA-45.7M
10-Day Moving Average2.91
P/E Ratio-4.77
20-Day Moving Average2.85
Forward P/E Ratio8.33
50-Day Moving Average2.61
Earnings per Share-0.77
200-Day Moving Average2.94
Profit Margin-Infinity%
RSI68.58
Shares Outstanding57.3M
ATR0.28
52-Week High4.94
Volume7,933,410
52-Week Low1.93
Most Recent Support Level2.50
Book Value104.3M
Most Recent Resistance Level2.96
P/B Ratio1.98
Upper Keltner3.49
P/S RatioInfinity
Lower Keltner2.22
Debt-to-Equity Ratio3.49
Next Earnings Date08/05/2026
Cash Surplus15.5M
Next Ex-Dividend DateUnknown

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Black Diamond Therapeutics Inc In Our Stock Scanner

As of May 21, 2026
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Momentum StocksScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.